RPL22
RPL22 (Large ribosomal subunit protein eL22) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Colorectal cancer and Gastric & gastro-oesophageal junction cancer.
Overview
Component of the large ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell.
Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.90, genetic association 0.00, somatic mutation 0.83, clinical 0.11). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Hepatocellular Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RPL22 (Large ribosomal subunit protein eL22) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Colorectal cancer and Gastric & gastro-oesophageal junction cancer.
- 1 · What it is
RPL22 (Large ribosomal subunit protein eL22) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Colorectal cancer and Gastric & gastro-oesophageal junction cancer.
- 2 · What goes wrong in cancer
Component of the large ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell.
- 3 · How drugs use it
No product in this corpus aims at RPL22 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:10315 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P35268 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000116251 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: colorectal cancer 0.53, gastric cancer 0.53 (GraphQL API, CC0)); IntOGen RPL22 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Component of the large ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. Location: Cytoplasm (UniProt). Locus 1p36.31 (HGNC).
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Colorectal cancer: Open Targets association 0.53 with colorectal cancer (MONDO_0005575)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.53 with gastric cancer (MONDO_0001056)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.11; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"RPL22" OR ABSTRACT:"RPL22" OR TITLE:"ribosomal protein L22" OR ABSTRACT:"ribosomal protein L22" OR TITLE:"Large ribosomal subunit protein eL22" OR ABSTRACT:"Large ribosomal subunit protein eL22" OR TITLE:"L22" OR ABSTRACT:"L22" OR TITLE:"eL22" OR ABSTRACT:"eL22") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RPL22, not a curated reading list.